Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
Anti-Inflammatory Agents
/ therapeutic use
Antiviral Agents
/ therapeutic use
Arachidonic Acid
/ metabolism
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Diethylcarbamazine
/ therapeutic use
Drug Repositioning
Filaricides
/ therapeutic use
Humans
Inflammation
Lung
/ pathology
Pandemics
Pneumonia, Viral
/ drug therapy
Prostaglandins
/ metabolism
SARS-CoV-2
COVID-19 Drug Treatment
COVID-19
Corona
Diethyl carbamazine DEC
SARS-CoV-2
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
29
03
2020
revised:
24
04
2020
accepted:
12
05
2020
pubmed:
4
6
2020
medline:
12
9
2020
entrez:
4
6
2020
Statut:
ppublish
Résumé
SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19. Exploring compounds that could offer a breakthrough in treatment is the need of the hour. Re-positioning cheap, freely available and safe drugs is a priority. The paper proposes evidence for the potential use of diethylcarbamazine (DEC) in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid metabolism to prostaglandins, little known anti-viral effects on animal retroviruses and demonstrated anti-inflammatory actions in animal models of lung inflammation indicating the need to explore this hypothesis further. We believe this is the first time DEC is being proposed to treat COVID-19.
Identifiants
pubmed: 32492560
pii: S0306-9877(20)30563-6
pii: S0306-9877(20)30563-6
doi: 10.1016/j.mehy.2020.109843
pmc: PMC7232076
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antiviral Agents
0
Filaricides
0
Prostaglandins
0
Arachidonic Acid
27YG812J1I
Diethylcarbamazine
V867Q8X3ZD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109843Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.